COLL COLLEGIUM PHARMACEUTICAL, INCcompanySEC Filings & Insider Trading Activity 2026
Latest COLLEGIUM PHARMACEUTICAL, INC (COLL) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 7, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for COLLEGIUM PHARMACEUTICAL, INC (COLL) (SEC CIK 1267565), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Commercializes differentiated biopharmaceutical products for ADHD and moderate to severe pain in the U.S.
- • New: September 2024 acquisition of Ironshore adds Jornay PM, expanding into neuropsychiatry and ADHD market
Risk Factors
- • Cybersecurity risks overseen by Audit Committee with quarterly updates from Head of IT on incidents and infrastructure vulnerabilities
- • Potential impact from cybersecurity incidents managed by Head of IT with 20+ years experience and senior leadership for 10+ years
Management Discussion & Analysis
- • Revenue $780.6M in 2025, up $149.2M YoY from $631.4M; Jornay PM +$111.7M, Nucynta Products +$19.8M, Belbuca +$10.4M, Xtampza ER +$8.0M
- • Gross profit $463.3M vs $377.3M; operating expenses $284.8M vs $210.4M; operating income $179.6M vs $169.9M; operating margin ~23.0% vs ~26.9% (calculated from operating income/revenue)
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New FDA opioid labeling requirements effective July 31, 2025 mandate safety changes including overdose info, increasing compliance costs and marketing challenges
- • Most updated risk: $581.3M 2024 Term Loan and $241.5M 2029 Convertible Notes increase financial leverage and interest rate exposure via SOFR-linked variable rates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Announcement of AZSTARYS® acquisition signals strategic expansion of COLLEGIUM's ADHD portfolio and commercial footprint
- • Presentation and press release from March 19, 2026 provide details on acquisition rationale and expected financial impact
Item 1.01: Entry into a Material Definitive Agreement
- • Collegium Pharma to acquire AZSTARYS ADHD drug for $650M cash plus up to $135M in regulatory/commercial milestone payments
- • Acquisition targets GPC Commave Holding LLC and NewCo from Corium subsidiaries, expanding CNS stimulant portfolio
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced Feb 26, 2026
- • Full details in Exhibit 99.1 press release — key figures, guidance, and commentary found there
Item 7.01: Regulation FD Disclosure
- • Collegium Pharmaceutical (COLL) released an earnings presentation on Feb 26, 2026, covering latest reported period results
- • Full details in Exhibit 99.2 — primary source for revenue, earnings, and guidance figures
Annual Reports Archive10-K
AI-powered analysis of COLLEGIUM PHARMACEUTICAL, INC (COLL) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of COLLEGIUM PHARMACEUTICAL, INC (COLL) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | — | $566.8M | $631.4M | $780.6M |
| Gross Profit | $209.5M | $326.2M | $377.3M | $463.3M |
| Operating Income | — | $167.0M | $169.9M | $179.6M |
| Net Income | — | $48.2M | $69.2M | $62.9M |
| Gross Margin | — | 57.5% | 59.8% | 59.3% |
| Op. Margin | — | 29.5% | 26.9% | 23.0% |
| Net Margin | — | 8.5% | 11.0% | 8.1% |
| Balance Sheet | ||||
| Total Assets | $1.2B | $1.1B | $1.7B | $1.7B |
| Equity | — | $195.4M | $228.8M | $301.7M |
| ROE | — | 24.6% | 30.2% | 20.8% |
Source: XBRL financial data from COLLEGIUM PHARMACEUTICAL, INC (COLL) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 7, 2026 | — | — | — |
8-K | Mar 19, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 8, 2026 | — | — | |
8-K | Dec 30, 2025 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 22, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Feb 24, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — |
Frequently Asked Questions
What are the latest COLL SEC filings in 2026?
COLLEGIUM PHARMACEUTICAL, INC (COLL) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 7, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did COLL file its most recent 10-K annual report?
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view COLL 10-Q quarterly reports?
COLLEGIUM PHARMACEUTICAL, INC (COLL)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every COLL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has COLL filed recently?
COLLEGIUM PHARMACEUTICAL, INC (COLL)'s most recent 8-K was filed on April 7, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find COLL insider trading activity (Form 4)?
SignalX aggregates every COLL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does COLL file with the SEC?
COLLEGIUM PHARMACEUTICAL, INC (COLL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new COLL filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for COLLEGIUM PHARMACEUTICAL, INC (COLL).
What is COLL's SEC CIK number?
COLLEGIUM PHARMACEUTICAL, INC (COLL)'s SEC CIK (Central Index Key) number is 1267565. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1267565 to look up all COLL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find COLL return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from COLLEGIUM PHARMACEUTICAL, INC (COLL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of COLLEGIUM PHARMACEUTICAL, INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 49+ filings.